Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fady I Malik

Showing results (81-90 of 120) with videos related to

Pageof 12
Sort By:
JACC. Heart Failure|March 7, 2023
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HFDavid E Lanfear, Joyce N Njoroge, Kirkwood F Adams, et al.
Cardiovascular Drugs and Therapy|July 24, 2017
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics ConferenceThomas J Povsic, Rob Scott, Kenneth W Mahaffey, et al.
Journal of the American College of Cardiology|May 20, 2021
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HFJohn R Teerlink, Rafael Diaz, G Michael Felker, et al.
Circulation|September 5, 2025
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM TrialJoseph Campain, Catharine Griskowitz, Chloe Newlands, et al.
European Heart Journal|March 4, 2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term studyAlbree Tower-Rader, Ahmad Masri, Michael E Nassif, et al.
Circulation. Heart Failure|November 8, 2025
Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCMXiaowen Wang, Maria A Pabon, Tracy T Makuvire, et al.
Journal of the American College of Cardiology|October 30, 2024
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCMAhmad Masri, Lubna Choudhury, Roberto Barriales-Villa, et al.
Journal of the American College of Cardiology|September 1, 2024
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic CardiomyopathySheila M Hegde, Brian L Claggett, Xiaowen Wang, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 24, 2021
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating StudyStacy A Rudnicki, Jinsy A Andrews, Tina Duong, et al.
Lancet (London, England)|August 23, 2011
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trialJohn G F Cleland, John R Teerlink, Roxy Senior, et al.
Pageof 12

Showing results (81-90 of 120) with videos related to

Sort By:
Pageof 12
JACC. Heart Failure|March 7, 2023
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction: Insights From GALACTIC-HFDavid E Lanfear, Joyce N Njoroge, Kirkwood F Adams, et al.
Cardiovascular Drugs and Therapy|July 24, 2017
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics ConferenceThomas J Povsic, Rob Scott, Kenneth W Mahaffey, et al.
Journal of the American College of Cardiology|May 20, 2021
Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HFJohn R Teerlink, Rafael Diaz, G Michael Felker, et al.
Circulation|September 5, 2025
Characterization and Application of Novel Exercise Recovery Patterns That Reflect Cardiac Performance: A Substudy of the SEQUOIA-HCM TrialJoseph Campain, Catharine Griskowitz, Chloe Newlands, et al.
European Heart Journal|March 4, 2026
Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term studyAlbree Tower-Rader, Ahmad Masri, Michael E Nassif, et al.
Circulation. Heart Failure|November 8, 2025
Effect of Aficamten in Women Compared with Men with Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCMXiaowen Wang, Maria A Pabon, Tracy T Makuvire, et al.
Journal of the American College of Cardiology|October 30, 2024
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCMAhmad Masri, Lubna Choudhury, Roberto Barriales-Villa, et al.
Journal of the American College of Cardiology|September 1, 2024
Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic CardiomyopathySheila M Hegde, Brian L Claggett, Xiaowen Wang, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|February 24, 2021
Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating StudyStacy A Rudnicki, Jinsy A Andrews, Tina Duong, et al.
Lancet (London, England)|August 23, 2011
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trialJohn G F Cleland, John R Teerlink, Roxy Senior, et al.
Pageof 12